A PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE DEVICE EFFICACY BETWEEN THE
HELIXAR ELECTROSURGICAL GENERATOR (HEG) VS. CONVENTIONAL ELECTROSURGICAL COAGULATION
(CEC) FOR CUTTING AND/OR COAGULATION OF TISSUE DURING MASTECTOMY PROCEDURES
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04165525.
The objective of this study is to evaluate device efficacy between the HelixAR
Electrosurgical Generator (HEG) and Conventional Electrosurgical Coagulation (CEC)
Systems for cutting and/or coagulation of tissue during mastectomy procedures and
reconstructive surgery.
The study is designed and powered to demonstrate the superiority of the HEG to CEC in
relation to a key efficacy measure: post-mastectomy procedure time to hemostasis.
Secondary outcome measures include: infection, drain duration, total drain output, blood
loss, and device related adverse events. These outcomes will be evaluated in a controlled
population undergoing mastectomy procedures.
Trial PhaseNo phase specified
Trial Typetreatment
Lead OrganizationSurgiQuest, Inc.